Immunology Market to Reach $204.0 Billion, Globally, by 2033 at 6.3% CAGR: Allied Market Research
Increase in prevalence of chronic diseases, rise in awareness and understanding of immune-related diseases, and increase in investment in research and developmentare the major factors which drive the global market growth.
Wilmington, Delaware, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Allied Market Research published a report, titled, "Immunology Market by Product Type (Diagnostic Testing Equipment, Biomarkers and Biopharmaceuticals), Application (Allergy and Hypersensitivity, Autoimmune Disease, Infectious Disease, HIV and AIDS and Others), and End User (Hospitals and Clinics, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories and Others): Global Opportunity Analysis and Industry Forecast, 2024-2033". According to the report, the immunology market was valued at $110.1 billion in 2023, and is estimated to reach $204.0 billion by 2033, growing at a CAGR of 6.3% from 2024 to 2033.
Prime determinants of growth
Increase in prevalence of chronic diseases, rise in awareness and understanding of immune-related diseases, and increase in investment in research and development are the major factors that drive the growth of the immunology market. However, stringent regulatory requirements restricts the market growth. Moreover, advancements in biotechnology and molecular biology offers remunerative opportunities for the expansion of the global immunology market.
Request Sample of the Report on Immunology Market Forecast 2033 - https://www.alliedmarketresearch.com/request-sample/A298165
Recent Developments
- In March 2024, Gilead Sciences, Inc. and Xilio Therapeutics, Inc. announced an exclusive license agreement to develop and commercialize Xilio’s Phase 1 tumor-activated IL-12 program, XTX301. Xilio Therapeutics is a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies.
- In May 2023, Gilead Sciences, Inc. and Arcus Biosciences, Inc. announced that the companies have expanded the previously announced research collaboration focused on oncology to include therapies for the treatment of inflammatory diseases. The expanded collaboration builds upon Gilead’s growing presence in inflammatory disease and serves as a step towards broadening Arcus’ capabilities and portfolio beyond oncology and into inflammation.
Want to Explore More, Connect to our Analyst - https://www.alliedmarketresearch.com/connect-to-analyst/A298165
Segment Highlights
The biopharmaceuticals segment to maintain its leadership status during the forecast period
By product type, biopharmaceuticals segment dominated the market share in 2023. This is attributed to biopharmaceuticals offer targeted and precise mechanisms of action, resulting in enhanced efficacy and safety profiles compared to conventional drugs. The ongoing therapeutic innovations, expanding indications, rise in investment in R&D, coupled with advancements in biotechnology and personalized medicine approaches propel the segment growth.
The autoimmune disease segment to maintain its leadership status during the forecast period
By application, autoimmune disease segment dominated the market share in 2023. The increase in prevalence of autoimmune disorders worldwide is driving significant attention and investment towards research, diagnosis, and treatment options. With growing awareness and improved diagnostic techniques, more cases are being identified, leading to a greater demand for effective therapies.
The hospitals and clinics segment to maintain its leadership status during the forecast period
By end user, hospitals and clinics segment dominated the market share in 2023. Hospitals and clinics serve as primary points of care for patients with immunological disorders, providing comprehensive diagnostic, therapeutic, and follow-up services. In addition, the rise in prevalence of autoimmune and inflammatory conditions necessitates increased patient access to specialized healthcare facilities for timely diagnosis and treatment thereby driving the segment growth. Furthermore, these healthcare settings serve as hubs for clinical research and trials, driving innovation and advancements in immunology treatments which further support the segment growth.
For Purchase Related Queries/Inquiry - https://www.alliedmarketresearch.com/purchase-enquiry/A298165
Regional Outlook
North America to maintain its dominance by 2033
In North America and Europe there is a robust market for immunology due to advanced healthcare systems, rise in prevalence of chronic pain conditions, and greater accessibility to healthcare services. These regions also witness significant research and development activities, leading to the introduction of innovative pain management therapies and medications. In emerging markets such as Asia-Pacific and LAMEA the immunology market is experiencing rapid growth driven by increasing healthcare expenditure, expanding pharmaceutical industries, and rising awareness about pain management.
Key Players
- AbbVie Inc.
- Johnson & Johnson
- Pfizer Inc.
- Novartis AG
- Merck & Co., Inc.
- Bristol-Myers Squibb Company
- Amgen Inc
- Eli Lilly and Company
- Gilead Sciences, Inc.
- Sanofi
Get Customized Reports with your Requirements - https://www.alliedmarketresearch.com/request-for-customization/A298165
The report provides a detailed analysis of these key players in the global immunology market. These players have adopted different strategies such as agreement, collaboration, partnership, acquisition, and others to increase their market share and maintain dominant shares in different regions. The report is valuable in highlighting business performance, operating segments, product portfolio, and strategic moves of market players to showcase the competitive scenario.
Trending Reports in Healthcare Industry:
Radiology Information System Market - Global Opportunity Analysis and Industry Forecast, 2023-2032
Animal Model Market - Global Opportunity Analysis and Industry Forecast, 2023-2032
Cluster Headache Market - Global Opportunity Analysis and Industry Forecast, 2023-2032
AVENUE- A Subscription-Based Library (Premium on-demand, subscription-based pricing model) Offered by Allied Market Research:
AMR introduces its online premium subscription-based library Avenue, designed specifically to offer cost-effective, one-stop solution for enterprises, investors, and universities. With Avenue, subscribers can avail an entire repository of reports on more than 2,000 niche industries and more than 12,000 company profiles. Moreover, users can get an online access to quantitative and qualitative data in PDF and Excel formats along with analyst support, customization, and updated versions of reports.
Get an access to the library of reports at any time from any device and anywhere. For more details, follow the link: https://www.alliedmarketresearch.com/library-access
About Allied Market Research:
Allied Market Research (AMR) is a full-service market research and business-consulting wing of Allied Analytics LLP based in Wilmington, Delaware. Allied Market Research provides global enterprises as well as medium and small businesses with unmatched quality of "Market Research Reports" and "Business Intelligence Solutions." AMR has a targeted view to provide business insights and consulting to assist its clients to make strategic business decisions and achieve sustainable growth in their respective market domains. AMR offers its services across 11 industry verticals including Life Sciences, Consumer Goods, Materials & Chemicals, Construction & Manufacturing, Food & Beverages, Energy & Power, Semiconductor & Electronics, Automotive & Transportation, ICT & Media, Aerospace & Defense, and BFSI.
We are in professional corporate relations with various companies and this helps us in digging out market data that helps us generate accurate research data tables and confirms utmost accuracy in our market forecasting. Allied Market Research CEO Pawan Kumar is instrumental in inspiring and encouraging everyone associated with the company to maintain high quality of data and help clients in every way possible to achieve success. Each and every data presented in the reports published by us is extracted through primary interviews with top officials from leading companies of domain concerned. Our secondary data procurement methodology includes deep online and offline research and discussion with knowledgeable professionals and analysts in the industry.
Contact
David Correa
1209 Orange Street,
Corporation Trust Center,
Wilmington, New Castle,
Delaware 19801 USA.
Toll Free: +1-800-792-5285
Int’l: +1-503-894-6022
UK: +44-845-528-1300
Hong Kong: +852-301-84916
India (Pune): +91-20-66346060
Fax: +1-855-550-5975
Web: https://www.alliedmarketresearch.com
Follow Us on: LinkedIn Twitter
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
